Pradžia › Kartotinė mieloma › Indianas › Indianapolis
Kartotinė mieloma klinikiniai tyrimai Indianapolis, IN
13 tyrimai dėl Kartotinė mieloma ieško dalyvių vietose Indianapolis ir aplinkui (apytiksliai 30 mylių spinduliu). Atidarykite tyrimą, kad pamatytumėte, kas gali dalyvauti ir kaip susisiekti su tyrimo komanda.
Oficialus tyrimo tekstas (anglų kalba)
Ieškote dalyvių tyrimui? Pateikite jį šio puslapio viršuje – $99 už 30 dienų →
A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
Renkami dalyviai3 fazė
- Franciscan Health, Indianapolis
A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel
Renkami dalyviai4 fazė
- Indiana University, Indianapolis
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
Renkami dalyviai2 fazė
- Community Health Network (The University of Texas MD Anderson Cancer Center), Indianapolis
Collection of Tissue Samples for Cancer Research
Renkami dalyviaiStebimasis tyrimas
- Indiana University - Purdue, Indianapolis
MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
Renkami dalyviai3 fazė
- Community Health Network, Inc., Indianapolis
- Community Health Network, Inc., Indianapolis
- Community Health Network, Inc., Indianapolis
Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
Renkami dalyviai3 fazė
- Indiana University/Melvin and Bren Simon Cancer Center, Indianapolis
- IU Health Methodist Hospital, Indianapolis
A Study to Learn About the Effects of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma Subjects
Renkami dalyviai1 fazė
- Indiana University, Indianapolis
A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma
Renkami dalyviai2 fazė
- Indiana University Health, Indianapolis
A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma
Renkami dalyviai1 fazė
- Franciscan St. Francis Health /ID# 280928, Indianapolis
A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Participants With Multiple Myeloma That is Resistant to Current Standard of Care Treatments
Renkami dalyviai1 fazė
- Indiana University Health Simon Cancer Center, Indianapolis
Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies
Renkami dalyviai1/2 fazė
- Community Health Network, Indianapolis
Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment
Renkami dalyviai3 fazė
- Indiana University/Melvin and Bren Simon Cancer Center, Indianapolis
- Saint Catherine Hospital, Indianapolis
The Indiana Myeloma Registry
Renkami dalyviaiStebimasis tyrimas
- Indiana University Simon Cancer Center, Indianapolis
Kartotinė mieloma tyrimai kituose miestuose
- New York City, NY60 tyrimai
- Boston, MA42 tyrimai
- Atlanta, GA41 tyrimas
- Houston, TX38 tyrimai
- Durham, NC37 tyrimai
- Nashville, TN32 tyrimai
- Denver, CO27 tyrimai
- Rochester, MN24 tyrimai
- St. Louis, MO24 tyrimai
- Columbus, OH24 tyrimai
- Baldwin Park, CA23 tyrimai
- Chicago, IL22 tyrimai
Kiti tyrimai Indianapolis
- Nedidelinių ląstelių plaučių vėžys32 tyrimai
- Vėžys (visų tipų)24 tyrimai
- Širdies nepakankamumas23 tyrimai
- Krūties vėžys20 tyrimai
- Nutukimas20 tyrimai
- Metastatinis vėžys19 tyrimai
- Storosios ir tiesiosios žarnos vėžys18 tyrimai
- Kiaušidžių vėžys17 tyrimai
- Plaučių vėžys16 tyrimai
- Širdies ir kraujagyslių ligos16 tyrimai
- 1 tipo cukrinis diabetas14 tyrimai
- Endometrio vėžys14 tyrimai
Iš ClinicalTrials.gov, duomenys gauti 2026-10-05. Kiekvienas tyrimas nustato savo tinkamumo kriterijus; tyrimo komanda sprendžia, kas gali dalyvauti.